Belmont Capital’s AbCellera Biologics ABCL Stock Holding History

Belmont Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-260,000	Closed	-$770K	–	169
2024 Q2	$770K	Hold	260,000	–	–	0.14%	55
2024 Q1	$1.18M	Sell	260,000 -250,000	-49%	-$1.28M	0.32%	32
2023 Q4	$2.91M	Hold	510,000	–	–	1.24%	12
2023 Q3	$2.35M	Hold	510,000	–	–	1.27%	11
2023 Q2	$3.29M	Hold	510,000	–	–	1.85%	11
2023 Q1	$3.85M	Hold	510,000	–	–	3.18%	8
2022 Q4	$5.17M	Hold	510,000	–	–	5.53%	6
2022 Q3	$5.04M	Buy	510,000 +460,000	+920%	+$5.05M	5.95%	5
2022 Q2	$533K	Sell	50,000 -50,000	-50%	-$423K	0.65%	15
2022 Q1	$975K	Sell	100,000 -50,000	-33%	-$473K	0.97%	7
2021 Q4	$2.15M	Hold	150,000	–	–	1.68%	8
2021 Q3	$3.01M	Hold	150,000	–	–	2.44%	6
2021 Q2	$3.3M	Buy	+150,000	New	+$4.14M	3.4%	5

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Belmont Capital's ABCL Position: Q3 2024 in Review

Belmont Capital sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 260,000 shares — an estimated $770K sold.

Belmont Capital first reported a position in ABCL in Q2 2021 and held it in 13 quarters. The position peaked at $5.17M in Q4 2022. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Belmont Capital reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
Belmont Capital sold 260,000 AbCellera Biologics shares in Q3 2024, an estimated $770K.
Belmont Capital first reported a position in AbCellera Biologics in Q2 2021 and held it in 13 quarters.
Belmont Capital's AbCellera Biologics position peaked at $5.17M in Q4 2022.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Belmont Capital's 13F filing for Q3 2024, filed 7 Nov 2024.